SCHEMBL15074682

SCHEMBL15074682

CNC(=S)NC(=O)Cc1ccc(C(=O)OC)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.54
KMT2A Q03164 7/20 0.52
MEN1 O00255 6/20 0.52
MAPK1 P28482 1/20 0.52
RAB9A P51151 3/20 0.51
NPC1 O15118 3/20 0.51
LMNA P02545 3/20 0.51
LOXL2 Q9Y4K0 1/20 0.50
CRHBP P24387 3/20 0.48
CRHR2 Q13324 3/20 0.48
RXFP1 Q9HBX9 1/20 0.48
GAA P10253 2/20 0.47
CYP4A11 Q02928 2/20 0.46
MAPT P10636 2/20 0.46
CYP4F2 P78329 1/20 0.45
ALDH1A1 P00352 2/20 0.45
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14817477 0.84 KDM4E (0.52) TDP1KMT2AMEN1MAPK1RAB9A
SCHEMBL169824 0.83 TDP1 (0.76) TDP1KMT2AMEN1RAB9ANPC1
SCHEMBL17993528 0.83 LOXL2 (0.56) TDP1KMT2AMEN1MAPK1RAB9A
SCHEMBL14873200 0.81 LMNA (0.57) TDP1KMT2AMEN1RAB9ANPC1
SCHEMBL171965 0.80 LMNA (0.55) TDP1KMT2AMEN1MAPK1RAB9A
SCHEMBL171909 0.79 CRHBP (0.58) TDP1KMT2AMEN1RAB9ALMNA
SCHEMBL20878928 0.78 LMNA (0.54) TDP1KMT2AMEN1RAB9ANPC1
SCHEMBL1811746 0.77 LOXL2 (0.59) TDP1KMT2AMEN1MAPK1RAB9A
SCHEMBL171948 0.77 KMT2A (0.78) TDP1KMT2AMEN1MAPK1LMNA
SCHEMBL1198999 0.76 LOXL2 (0.62) TDP1KMT2AMEN1MAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9018378-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2015-04-28 US disclosed
US-8907091-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2014-12-09 US disclosed
US-8846927-B2 Inhibitors of protein tyrosine kinase activity METHYLGENE INC. (CA) 2014-09-30 US disclosed
US-8569503-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2013-10-29 US disclosed
US-20130165477-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC. (CA) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165477-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY HGF, ERBB2, MET TDP1 2357/4885KMT2A 2353/4885MEN1 3231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.